Skip to main content

Drug Interactions between digoxin and solifenacin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

digoxin solifenacin

Applies to: digoxin and solifenacin

Anticholinergic agents may increase the absorption and oral bioavailability of some digoxin formulations. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents. In one study, coadministration with propantheline (15 mg three times a day for 10 days) led to a 30% mean increase in serum digoxin levels in 9 of 13 elderly women receiving a slow-dissolution formulation of digoxin. The interaction has also been reported with formulations containing large particle size digoxin. Other studies have found no significant effect of propantheline on digoxin elixir, solution in capsules, rapid-dissolution tablets, and micronized digoxin tablets. Therefore, the interaction is not expected to occur with most digoxin products used today in industrialized countries (e.g., Lanoxin). Due to the drug's narrow therapeutic index, however, clinicians may consider monitoring patients more closely for digoxin side effects and toxicity during coadministration with anticholinergic agents. Patients should be advised to notify their physician if they experience potential signs and symptoms of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, and irregular heartbeats.

References (5)
  1. Brown DD, Schmid J, Long RA, Hull JH (1985) "A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules." J Clin Pharmacol, 25, p. 360-4
  2. Binnion PF, McDermott M, LeSher D (1973) "Bioavailability of digoxin." Lancet, 1, p. 1118
  3. Johnson BF, O'Grady J, Bye C (1978) "The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide." Br J Clin Pharmacol, 5, p. 465-7
  4. Manninen V, Apajalahti A, Simonen H, Reissell P (1973) "Effect of propantheline and metoclopramide on absorption of digoxin." Lancet, 1, p. 1118-9
  5. (2001) "Product Information. Lanoxicaps (digoxin)." Glaxo Wellcome

Drug and food interactions

Minor

digoxin food

Applies to: digoxin

Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.

Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.

References (2)
  1. Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
  2. Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.